Tempus
$7Bmarket cap
// OVERVIEW
Tempus built a $7 billion precision medicine business by convincing hospital systems to send it their most sensitive patient data, then selling AI-driven clinical insights back to the same institutions that generated the data. The company went public in June 2024 at a $6.1 billion valuation and immediately began the Silicon Valley tradition of losing money while claiming the future of oncology depends on its algorithms.
// HQ
Chicago, United States
// STATUS
PUBLIC
// FOUNDED
2015
// TIER
The Unicorn Herd · $1B – $9.9B
// PRIMARY SECTOR
ai
// FOUNDERS
// FUNDING ROUNDS
// SECTORS SERVED
// TECHNOLOGY
Tempus operates the largest library of clinical and molecular data in oncology — over 7.5 million de-identified patient records linked to genomic sequencing, pathology imaging, and treatment outcomes. The platform uses machine learning models trained on this proprietary dataset to recommend personalized cancer treatments, predict drug response, and identify clinical trial candidates. The moat is the data flywheel: more patients generate better predictions which attract more hospital partnerships which generate more patients.
// WOWLS ASSESSMENT
Tempus generated $532 million in revenue in 2023, up 66% year-over-year, but burned $214 million doing it — which means the company is still $0.40 in the red for every dollar it earns convincing oncologists that its algorithms are better than their clinical judgment. The business model has three components: genomic testing services (58% of revenue), data licensing to pharmaceutical companies (32%), and AI algorithm subscriptions to providers (10%). The pharmaceutical partnerships are the strategic bet — Tempus has contracts with 50 of the top 50 biopharma companies, selling access to de-identified patient cohorts for drug development and trial recruitment. The risk is regulatory: the FDA has not yet decided whether AI-driven treatment recommendations constitute medical devices requiring pre-market approval, and if that classification lands Tempus will face the same approval gauntlet that has buried every previous generation of clinical decision support software. Rivals include Foundation Medicine (owned by Roche), Guardant Health ($3.2B market cap), and Freenome, but none have matched Tempus's dataset scale or pharmaceutical sales depth.
// WHY WOWLS HUNTS THIS
The company has convinced 50 of the top 50 pharmaceutical companies to pay for access to its patient data library, which means Tempus has successfully monetized the clinical information that hospital systems gave it for free. WOWLS admires businesses built on elegant arbitrage between the institution that generates the asset and the institution willing to pay for it.
VERDICT: ARMED — TEMPUS WENT PUBLIC AT $6.1B IN JUNE 2024 AND IS NOW WORTH $7B, WHICH MEANS THE MARKET IS PRICING IN THE POSSIBILITY THAT ONCOLOGISTS WILL EVENTUALLY TRUST AN ALGORITHM TRAINED ON 7.5 MILLION PATIENT RECORDS MORE THAN THEY TRUST THEIR OWN RESIDENCY TRAINING
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track Tempus.
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on Tempus?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN